Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 13:17:1079-1090.
doi: 10.2147/JMDH.S451835. eCollection 2024.

Pharmacists' Attitudes Towards Long-Term Use of Nasal Decongestants: A Cross-Sectional Study

Mohammad M Mokhatrish  1 , Sharif D Almatrafi  1 , Turki M Aldrees  1 , Turki A Aldriweesh  1 , Fahad M AlGhamdi  2 , Abdullah S Al-Dosary  3 , Naif K Alhumaydani  3 , Osamah Z Aldakkan  3 , Naif Alrudian  3 , Ali Hassan Ali  3
Affiliations

Pharmacists' Attitudes Towards Long-Term Use of Nasal Decongestants: A Cross-Sectional Study

Mohammad M Mokhatrish et al. J Multidiscip Healthc. .

Abstract

Background: Rhinitis medicamentosa is a nonallergic inflammation of the nasal mucosa caused by topical decongestants overuse. It mainly affects young and middle-aged adults. Therefore, the aim of this study was to investigate the attitudes of pharmacists regarding the utilization of over-the-counter intranasal decongestants.

Methods: An online cross-sectional study was conducted from November 2021 to January 2022. The target population of the study included pharmacists who work in community pharmacies in Saudi Arabia. Binary logistic regression analysis was used to identify predictors of having positive attitude towards controlling the use of decongestant.

Results: A total of 220 participants were included in this study. Around 15.0% of them reported that ND come with a physician prescription. The majority of the participants (87.3%) reported that the less than 5 days is the maximum safe duration for the use of NDs. Overall, the study participants demonstrated moderately positive attitude towards controlling the use of decongestant with a mean attitude score of 2.5 (standard deviation: 1.2) out of 5; which represents 50.0% of the maximum score. Binary logistic regression analysis identified that pharmacists aged 31-40 years were two-folds more likely to have positive attitude towards controlling the use of decongestant compared to others (p<0.05). Around 45.9% of them reported that they recommend other over-the-counter treatments like nasal irrigation, nasal steroids, or antihistamine if they see a patient with RM asking for ND with or without prescription.

Conclusion: The majority of pharmacists in Saudi Arabia demonstrated sufficient awareness and understanding on the adverse effects associated with the excessive use of NDs. Rhinitis medicamentosa can be avoided by appropriate measures, highlighting the importance of raising awareness about the excessive use of decongestants among healthcare professionals and patients alike.

Keywords: Saudi Arabia; attitude; nasal decongestants; pharmacist; rhinitis medicamentosa.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests in this work.

Figures

Figure 1
Figure 1
Most prevalent symptoms of patients asking for NDs.
Figure 2
Figure 2
Methods of improving public awareness regarding NDs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Meltzer EO, Caballero F, Fromer LM, Krouse JH. Scadding G: treatment of congestion in upper respiratory diseases. Int J Gene Med. 2010;3:69–91. doi:10.2147/ijgm.s8184 - DOI - PMC - PubMed
    1. Lenz D, Cardoso K, Bitti A, Andrade T. Evaluation of the use of topic nasal decongestants in university students from health sciences courses. Braz J Pharm Sci. 2011;47(4):761–767. doi:10.1590/S1984-82502011000400013 - DOI
    1. Schroer B, Pien LC. Nonallergic rhinitis: common problem, chronic symptoms. Cleveland Clin j med. 2012;79(4):285–293. doi:10.3949/ccjm.79a11099 - DOI - PubMed
    1. Dykewicz MS, Wallace DV, Amrol DJ, et al. Steven GC: rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146:721–767. doi:10.1016/j.jaci.2020.07.007 - DOI - PubMed
    1. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med. 2005;4:21–29. doi:10.2165/00151829-200504010-00003 - DOI - PubMed